Ordög T, Hayashi Y, Gibbons S J
Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
Minerva Gastroenterol Dietol. 2009 Sep;55(3):315-43.
Gastroenteropathy manifesting in upper gastrointestinal symptoms, delayed gastric emptying, constipation, diarrhea and fecal incontinence occurs frequently in patients with diabetes mellitus and represents a significant health care burden. Current treatments are largely symptomatic and ineffective. Better understanding of the cellular and molecular pathogenesis of these disorders is required for the development of more effective therapies. Recent advances in our understanding of the inherent, high-level complexities of the control systems that execute and regulate gastrointestinal motility, together with the utilization of new experimental models and sophisticated physiological, morphological and molecular techniques have lead to the realization that diabetic gastroenteropathies cannot be ascribed to any singular defect or dysfunction. In fact, these disorders are multifactorial and involve a spectrum of metabolic and dystrophic changes that can potentially affect all key components of motor control including the systemic autonomic and enteric nervous systems, interstitial cells of Cajal and smooth muscle cells. Candidate pathomechanisms are also varied and include imbalance between pro- and anti-oxidative factors, altered trophic stimuli to mature cells and their progenitors, and, possibly, autoimmune factors. The goal of this paper is to review the cellular changes underlying diabetic gastroenteropathies and their potential causes, with particular focus on functional interactions between various cell types. It is proposed that diabetic gastroenteropathies should be considered a form of gastrointestinal neuromuscular dystrophy rather than a "functional" disorder. Future research should identify ways to block cytotoxic factors, support the regeneration of damaged cells and translate the experimental findings into new treatment modalities.
糖尿病患者常出现表现为上消化道症状、胃排空延迟、便秘、腹泻及大便失禁的胃肠病,这构成了一项重大的医疗负担。目前的治疗大多只是对症治疗,效果不佳。要开发更有效的治疗方法,需要更好地了解这些疾病的细胞和分子发病机制。我们对执行和调节胃肠动力的控制系统内在的高度复杂性有了新的认识,同时利用新的实验模型以及精密的生理学、形态学和分子技术,这使人们认识到糖尿病胃肠病不能归因于任何单一的缺陷或功能障碍。事实上,这些疾病是多因素的,涉及一系列代谢和营养不良性变化,可能会影响运动控制的所有关键组成部分,包括全身自主神经系统和肠神经系统、 Cajal间质细胞和平滑肌细胞。候选发病机制也多种多样,包括促氧化和抗氧化因子之间的失衡、对成熟细胞及其祖细胞的营养刺激改变,以及可能的自身免疫因素。本文的目的是综述糖尿病胃肠病潜在病因的细胞变化,特别关注各种细胞类型之间的功能相互作用。有人提出,糖尿病胃肠病应被视为胃肠神经肌肉营养不良的一种形式,而不是一种“功能性”疾病。未来的研究应确定阻断细胞毒性因子的方法,支持受损细胞的再生,并将实验结果转化为新的治疗方式。